Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same

ABSTRACT

The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

TECHNICAL FIELD

The present invention relates to an inclusion compound of fumagillolderivative or its salt with hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin, and pharmaceutical compositionscomprising the same.

BACKGROUND ART

Cyclodextrins are cyclic compounds consisting of glucopyranose unitsthrough α-1,4-glycosidic linkages. The exterior surface of thecyclodextrin ring is hydrophilic, whereas the inside cavity thereofexhibits a hydrophobic character. Therefore, it is possible that othermolecules referred to as “guest molecule” or part thereof, which areless polar than water (hydrophobic molecules) and have suitabledimensions to be required to fit into the cyclodextrin cavity, areincluded in the hydrophobic cavity of the cyclodextrin molecule and forminclusion compounds. The pharmaceutical applications with cyclodextrinsare disclosed in many articles (Journal of Parenteral Science &Technology 43(5), pp 231-240 (1989) and Pharmaceutical Research 14(5),pp 556-567 (1997)).

Cyclodextrins consisting of 6, 7 or 8 glucopyranose units are generallyreferred to as α-, β- and γ-cyclodextrin, respectively. Althoughβ-cyclodextrin is the most useful one of the above natural cyclodextrinsfor pharmaceutical preparations in terms of inclusion capacity andeconomical efficiency, it is not always ideal for drug formulations dueto its relatively low aqueous solubility (1.8 g per 100 ml of water),serious renal toxicity and biological membrane incompatibility afterparenteral administration. Therefore, its application is limited tomerely food products or oral pharmaceutical preparations.

Recently, a number of chemically modified cyclodextrins such asalkylated-, hydroxyalkylated-, carboxyethylated- andsulfoalkylether-cyclodextrins have been prepared to improve theinclusion capacity and physicochemical properties of naturalcyclodextrins.

Among them, as hydroxyalkylated group, C₁₋₆ alkyl group is preferable,and hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groupcan be enumerated. In particular, hydroxypropyl group is preferable. Inaddition, as sulfoalkylated group, C₁₋₆ alkyl group is preferred, andsulfomethyl, sulfoethyl, sulfopropyl and sulfobutyl group can beenumerated. In particular, sulfobutyl group is preferable. The specificproduct in the hydroxyalkylated cyclodextrins includes2-hydroxypropyl-β-cyclodextrin, and the specific product in thesulfoalkylether cyclodextrins includes sufobutylether-7-β-cyclodextrin.Hydroxypropyl-β-cyclodextrin and sulfobutylether-7-β-cyclodextrin areespecially suitable for the parenteral application because of their highwater-solubility and minimal-toxicity, which are well disclosed inJournal of Pharmaceutical Science 85(11), pp 1142-1169 (1996).

Further, with regard to cyclodextrin inclusion compounds, U.S. Pat. No.4,371,673 discloses two types of water-soluble cyclodextrin complexeswith retinoid-polymers and complexes of retinoids with ether typederivatives of cyclodextrins. U.S. Pat. No. 4,596,795 discloses resultsfor administering a complex of sex hormone and cyclodextrin derivativevia sublingual and buccal route. And U.S. Pat. No. 4,727,064 describesresults on the conversion methods of drugs with ready crystallizationand low water-solubility into intrinsically amorphous complexes, whichhave improved pharmaceutical properties by using cyclodextrinderivatives. U.S. Pat. No. 5,134,127 discloses sulfoalkylethercyclodextrin derivatives and their use as solubilizing agents for poorlywater-soluble drugs for oral, intranasal or parenteral administration.

Recently, it has been proposed as a promising concept that solid tumorgrowth beyond a certain size requires newly-formed blood vessels for thetransport of nutrients and oxygen, which is called to beangiogenesis-dependent, and it is expected that the inhibition ofangiogenesis would provide a powerful and selective therapy for a widevariety of tumors. In particular, fumagillol derivative has beenreported to exhibit pharmacological properties as an effectiveinhibiting agent for tumor-induced neovascularization by European PatentNo. 415,294 and U.S. Pat. No. 6,063,812. However, further development ofthose compounds applicable to the clinical use is hampered considerablyby the fact that they are poorly soluble in water and very unstable atroom temperature.

It is well known that low drug solubility causes low absorption uponoral administration, precluding parenteral formulations. Furthermore,low stability imposes short shelf-life of products, low-temperaturestorage requirement and restrictions on mechanical movement, resultingin economical inefficiency and inconvenience.

Preparation studies of fumagillol derivatives are disclosed in severalliteratures. Solubility improvement of fumagillol derivatives wasestablished in U.S. Pat. No. 5,196,406, but the stabilization ofresulting products was not disclosed in the art. Other solubilityimprovement of fumagillol derivatives was established in European patentNo. 519,428 but organic solvents such as ethanol, acetonitrile,isopropyl alcohol and acetone rather than cyclodextrins contributed moreto the improved solubility. However, the use of organic solventpotentially may cause the side effects of the therapy. That is, furtherdilution in a large volume parenteral fluid such as saline or 5%dextrose solution on intravenous or intramuscular administration couldlead to life-threatening precipitation followed by phlebitis due to thelimited solubility. Also, in the art, stability was not consistentdepending on the particular kind of cyclodextrin derivative. Thestability of the mixture with maltosyl-β-cyclodextrin was improved,whereas the stability of the mixture with hydroxypropyl-β-cyclodextrinwas rather worse than the parent compound alone. In addition, though theformulation with maltosyl-β-cyclodextrin seemed to be stable,maltosyl-β-cyclodextrin has not been yet guaranteed for a parenteraluse, and its cost has made its universal use for various formulationseconomically unfavorable in contrast to hydroxypropyl-β-cyclodextrinthat proved to be safe and economical. Also, though a stable compositionof fumagillol derivatives was disclosed in U.S. Pat. No. 5,422,363, allexcipients, fatty acid esters of glycerin or polyglycerin, used in theformulations are not suitable for the parenteral application.

Therefore, there was a need to convert fumagillol derivatives into aform, which is better soluble and stable, and thus possesses improvedpharmaceutical properties.

Concerning the above, the inventors of the present invention developednovel fumagillol derivative and filed (U.S. Pat. No. 6,063,812), and thecompounds used in the present invention are identical to the compoundsdisclosed therein.

The present inventors continued studies to provide fumagillol derivativepreparations that can be applicable to parenteral administration such asintravenous or intramuscular injection, or oral administration byensuring homogeneity, safety, bioavailability and stability understorage at room temperature through increasing solubility of fumagillolderivatives or their salts which were found to be superior as anangiogenesis inhibitor but unstable under storage at room temperature orin aqueous solution. As a result, we discovered that the inclusioncompound of fumagillol derivative or its salt withhydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin isuseful as an antitumor agent or antimetastatic agent with superiorwater-solubility and stability but low irritancy effect, and based onthese, completed the present invention.

Therefore, the object of the present invention is to provide inclusioncompound of fumagillol derivative or its salt withhydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, andpharmaceutical composition comprising the same.

DISCLOSURE OF INVENTION

The present invention relates to the inclusion compound of fumagillolderivative of the following Formula 1 or its salt withhydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, andpharmaceutical compositions comprising the same:

Wherein,

-   -   X is hydroxy, Y is halogen, or X and Y together forms oxirane        ring    -   B is O or H₂; and    -   R₁, R₂, R₃, R₄ and R₅ independently represent hydrogen, hydroxy,        acetoxy, C₁-C₆ alkyl, C₁₋₆ alkoxy, amino, alkylamino,        dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl,        aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, halogen,        cyano, trifluoromethyl, nitro, formyl, acetamido,        methyleneoxycarboxy, methylenedioxy or ethylenedioxy group,    -   provided that R₁, R₂, R₃, R₄ and R₅ cannot be hydrogen at the        same time.)

Specifically, the inclusion compound of the present invention ischaracterized in that it includes angiogenesis inhibitor as a maincomponent, in particular fumagillol derivative of said Formula 1 or itssalt and as a solubilizing and stabilizing agent, cyclodextrinderivative, in particular hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin without addition of any organicsolvent.

Fumagillol derivative or its salt of the present invention is preferredto be the following compounds:

-   O-(4-chlorocinnamoyl)fumagillol;-   O-(4-aminocinnamoyl)fumagillol;-   O-(4-dimethylaminoethoxycinnamoyl)fumagillol-   O-(4-methoxycinnamoyl)fumagillol;-   O-(4-dimethylaminocinnamoyl)fumagillol;-   O-(4-hydroxycinnamoyl)fumagillol;-   O-(3,4-dimethoxycinnamoyl)fumagillol;-   O-(3,4-methylenedioxycinnamoyl)fumagillol;-   O-(3,4,5-trimethoxycinnamoyl)fumagillol;-   O-(4-nitrocinnamoyl)fumagillol;-   O-(3,4-dimethoxy-6-aminocinnamoyl)fumagillol;-   O-4-acetoxy-3,5-dimethoxycinnamoyl)fumagillol;-   O-(4-ethylaminocinnamoyl)fumagillol;-   O-(4-ethylaminoethoxycinnamoyl)fumagillol;-   O-(3-dimethylaminomethyl-4-methoxycinnamoyl)fumagillol;-   O-(4-trifluoromethylcinnamoyl)fumagillol;-   O-(3,4-dimethoxy-6-nitrocinnamoyl)fumagillol;-   O-(4-acetoxycinnamoyl)fumagillol;-   O-(4-cyanocinnamyl)fumagillol;-   4-(4-methoxycinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;-   O-(3,4,5-trimethoxycinnamyl)fumagillol;-   O-(4-dimethylaminocinnamoyl)fumagillol;-   O-(3,4,5-trimethoxycinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;-   O-(4-dimethylaminocinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;-   O-(3,5-dimethoxy-4-hydroxycinnamoyl)fumagillol; or a salt thereof.

More preferably, the fumagillol derivative or its salt according to thepresent invention is the following compounds:

-   4-(4-methoxycinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;-   O-(4-methoxycinnamoyl)fumagillol;-   O-(3,5-dimethyl-4-hydroxycinnamoyl)fumagillol;-   O-(4-dimethylaminoethoxycinnamoyl)fumagillol;-   O-(3,4,5-trimethoxycinnamoyl)fumagillol;-   O-(3,4-dimethoxy-6-aminocinnamoyl)fumagillol; or a salt thereof.

Further preferably, fumagillol derivative or its salt of the presentinvention is O-(4-dimethylaminoethoxycinnamoyl)fumagillol orO-(3,4,5-trimethoxycinnamoyl) fumagillol.

In addition, as the fumagillol derivative salt of the present invention,it is preferable to select from a group consisting of salts offumagillol derivative with hydrochloric acid, bromic acid, sulfuricacid, phosphoric acid, nitric acid, formic acid, acetic acid,trifluoroacetic acid, oxalic acid, fumaric acid, tartaric acid, maleicacid, methanesulfonic acid, benzenesulfonic acid or para-toluenesulfonicacid.

Fumagillol derivative represented with the formula 1 used in the presentinvention were disclosed in U.S. Pat. No. 6,063,812, and preparedaccording to the method disclosed therein.

The inclusion compound of the present invention can be prepared bydissolving hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin in distilled water, and addingfumagillol derivative or its salt under stirring, or can be prepared bydissolving hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin in distilled water, and addingfumagillol derivative or its salt under stirring after adjusting thesolution pH in a range of 6-8 with dilute hydrochloric acid or sodiumhydroxide solution.

In addition, the inclusion compound of the present invention can beprepared by dissolving hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin in buffer solution which pH waspre-adjusted in a range of 6-8 with phosphate buffer, and by addingfumagillol derivative or its salt under stirring.

The produced inclusion compound can be provided as pure product, i.e. inthe form of solution or in a solid form via lyophilization, and ifnecessary, before freeze drying, final solution obtained after shakingcan undergo pH adjustment step in the range of 6-8.

The Inclusion compound obtainable according to the present invention canbe used as various forms, e.g. solid or solution.

In this invention, it is preferred that the molar ratio of fumagillolderivative or its salt to hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin is 1:1 to 1:10, and more preferably,1:1 to 1:6.

The inclusion compound of fumagillol derivative or its salt according tothe present invention has superior solubility and stability compared toother preparations of fumagillol derivative.

As result of solubility evaluation with cosolvents and surfactants,O-(4-dimethylaminoethoxycinnanoyl)fumagillol exhibited the solubility ofabout 5 mg/ml in aqueous formulations containing a mixture of 10%ethanol and 10% Tween 80® or 10% Cremophor-EL® alone. However, theseformulations have a number of disadvantages, which are the inability toguarantee the long-term stability due to facile hydrolysis in solutionstate, the inability to be buffered due to increased sensitivity to ionsresulting in precipitation and further, the toxicity of the surfactants.

In contrast, the inclusion compound of the present invention has beenfound to have improved solubility over other formulations indicatedabove. For example, the solubility ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol is enhanced from 50 μg/mlin water to about 7 mg/ml in 7 w/v % hydroxypropyl-β-cyclodextrinsolution and about 30 mg/ml in 14% w/v hydroxypropyl-β-cyclodextrinsolution at pH 6.7, respectively. The solubility ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol is about 5.5 mg/ml in 7 w/v% sulfobutylether-7-β-cyclodextrin solution. Thus, depending the pH andthe concentration of hydroxypropyl-β-cyclodextrin orsulfobutylether-7-β-cyclodextrin present in solution, the aqueoussolubility of O-(4-dimethylaminoethoxycinnamoyl)fumagillol is found toincrease by 20-1000 fold.

In addition, the stability of the inclusion compound in the presentinvention was surprisingly improved at room temperature. The resultsshowed that the degradation rate ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol included inhydroxypropyl-β-cyclodextrin was decreased greatly in solid state atroom temperature, compared with that ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol alone. The preferredinclusion compound in the present invention also suppressed thehydrolysis rate of O-(4-dimethylaminoethoxycinnamoyl)fumagillol insolution.

Therefore, the inclusion compound in the present invention can beapplied to the parenteral or oral formulation, since it eliminates thedisadvantage of other formulations with cosolvents and surfactants. Thepreferred inclusion compound in the present invention also overcomesionic strength effects, which permits the use of buffers to control thepH of solution, and is fully dilutable because of a linear increase inthe solubility of the fumagillol derivative as function ofhydroxypropyl-β-cyclodextrin or sulfobutylether-β-cyclodextrinconcentration. Therefore, it can offer a wide choice of diluents such aselectrolytes and non-electrolytes.

The present invention is further characterized by providingpharmaceutical composition comprising the inclusion compound accordingto the present invention and pharmaceutically acceptable additives.

The pharmaceutically acceptable additives include diluents ofpharmaceutically acceptable electrolytes or non-electrolytes, buffers,flavoring agents, binders, thickeners, lubricants, preservatives and thelike, and the composition of the present invention can include at leastone selected from those ingredients.

Herein, it is preferable that said buffer included in the composition ofthe present invention is phosphate buffer.

The pharmaceutical formulation can be formulated into oral or parenteralpreparation. For parenteral preparation, injection, eye drop, nasalformulation can be enumerated, and preferred injection includessubcutaneous, intravenous, intramuscular, intraarterial and infusionadministrations.

Further, the pharmaceutical composition of the present invention can beformulated into the sustained-release dosage form.

The pharmaceutical composition according to the present invention can beused as an anti-tumor agent or a tumor metastasis inhibitor in humanbeings with tumor, and can also be used for the treatment inwarm-blooded animals such as rats, dogs, rabbits, cats and chickens.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows two-dimensional nuclear magnetic resonance spectrum (NOSEY)for the inclusion compound of fumagillol derivative in Example 12.

FIG. 2 represents respective plasma concentration-time curve afterintravenous administration of fumagillol derivative alone (●) and theinclusion compound of fumagillol derivative (◯) in Example 17.

BEST MODE FOR CARRYING OUT THE INVENTION

The following Examples represent preferred embodiments of the presentinvention. However, the present invention is not limited to thefollowing Examples.

Example 1

O-(4-dimethylaminoethoxycinnamoyl)fumagillol (30 mg) was added to 1:5,3.5, 7.0, 14.0, 28.0 w/v % hydroxypropyl-β-cyclodextrin solution,respectively, and stirred at 4° C. After 72 hr, the mixture was filteredwith 0.2 μm membrane filter andO-(4-dimethylaminoethoxycinnamoyl)fumagillol in the filtrate wasdetermined by high pressure liquid chromatography (HPLC). The solubilityof O-(4-dimethylamino ethoxycinnamoyl)fumagillol as a function of thehydroxypropyl-β-cyclodextrin concentration was represented in Table 1.

TABLE 1 Solubility Concentration of hydroxypropyl-β-cyclodextrin (w/v %)(mg/ml) 0 0.05 1.5 1.03 3.5 2.93 7.0 6.95 14.0 11.54 28.0 22.64

As in apparent from Table 1, the solubility ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol was improved whenhydroxypropyl-β-cyclodextrin was added to form a complex and when theconcentration of hydroxypropyl-β-cyclodextrin was increased.

Example 2

O-(4-dimethylaminoethoxycinnamoyl)fumagillol (30 mg) was added to 1.5,3.5, 7.0, 14.0, 28.0 w/v % sulfobutylether-7-β-cyclodextrin solution,respectively, and stirred at 4° C. After 72 hr, the mixture was filteredwith 0.2 μm membrane filter andO-(4-dimethylaminoethoxycinnamoyl)fumagillol in the filtrate wasdetermined by high pressure liquid chromatography (HPLC). The solubilityof O-(4-dimethylaminoethoxycinnamoyl)fumagillol as a function of thesulfobutylether-7-β-cyclodextrin concentration was represented in Table2.

TABLE 2 Solubility Concentration of sulfobutylether-7-β-cyclodextrin(w/v %) (mg/ml) 0 0.05 1.5 0.87 3.5 2.24 7.0 5.42 14.0 10.43 28.0 21.30

As in apparent from Table 2, the solubility ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol was improved whensulfobutylether-7-β-cyclodextrin was added to form a complex and whenthe concentration of sulfobutylether-7-β-cyclodextrin was increased.

Example 3

O-(3,4,5-trimethoxycinnamoyl)fumagillol (20 g) was added to 1.5, 3.5,7.0, 14.0, 28.0 w/v % hydroxypropyl-β-cyclodextrin solution,respectively, and stirred at 4° C. After 72 hr, the mixture was filteredwith 0.2 μm membrane filter and O-(3,4,5-trimethoxycinnamoyl)fumagillolin the filtrate was determined by high pressure liquid chromatography(HPLC). The solubility of O-(3,4,5-trimethoxycinnamoyl)fumagillol as afunction of the hydroxypropyl-β-cyclodextrin concentration was shown inTable 3.

TABLE 3 Solubility Concentration of hydroxypropyl-β-cyclodextrin (w/v %)(mg/ml) 0 0.002 1.5 0.43 3.5 1.52 7.0 3.54 14.0 6.72 28.0 12.02

As in apparent from Table 3, the solubility ofO-(3,4,5-trimethoxycinnamoyl)fumagillol was improved whenhydroxypropyl-β-cyclodextrin was added to form a complex and when theconcentration of hydroxypropyl-β-cyclodextrin was increased.

Example 4

O-(3,4,5-trimethoxycinnamoyl)fumagillol (20 mg) was added to 1.5, 3.5,7.0, 14.0, 28.0 w/v % sulfobutylether-7-β-cyclodextrin solution,respectively, and stirred at 4° C. After 72 hr, the mixture was filteredwith 0.2 μm membrane filter and O-(3,4,5-trimethoxycinnamoyl)fumagillolin the filtrate was determined by high pressure liquid chromatography(HPLC). The solubility of O-(3,4,5-trimethoxycinnamoyl) fumagillol as afunction of the sulfobutylether-7-β-cyclodextrin concentration was shownin Table 4.

TABLE 4 Solubility Concentration of sulfobutylether-7-β-cyclodextrin(w/v %) (mg/ml) 0 0.002 1.5 0.58 3.5 1.38 7.0 2.75 14.0 5.69 28.0 11.67

As in apparent from Table 4, the solubility ofO-(3,4,5-trimethoxycinnamoyl) fumagillol was improved whensulfobutylether-β-cyclodextrin was added to form a complex and when theconcentration of sulfobutylether-β-cyclodextrin was increased.

Example 5

O-(4-dimethylaminoethoxycinnamoyl)fumagillol (50 mg) was added tophosphate buffer (pH 6.7) containing 1.5, 3.5, 7.0 and 14.0 w/v %hydroxypropyl-β-cyclodextrin, respectively, and stirred at 4° C. After72 hr, the mixture was filtered with 0.2 μm membrane filter andO-(4-dimethylaminoethoxycinnamoyl)fumagillol in the filtrate wasdetermined by high pressure liquid chromatography (HPLC). The solubilityof O-(4-dimethylaminoethoxycinnamoyl)fumagillol as a function of thehydroxypropyl-β-cyclodextrin concentration was shown in Table 5.

TABLE 5 Solubility Concentration of hydroxypropyl-β-cyclodextrin(w/v %)(mg/ml) 0 2.38 1.5 4.24 3.5 9.86 7.0 17.59 14.0 32.25

As in apparent from Table 5, the solubility ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol was improved whenhydroxypropyl-β-cyclodextrin was added to form a complex and when theconcentration of hydroxypropyl-β-cyclodextrin was increased

Example 6

Hydroxypropyl-β-cyclodextrin (13 g) was put to mass flask and 60 ml ofdistilled water was added and stirred or subjected to sonication at 4°C. until clear solution was obtained. The pH of the solution wasadjusted in a range of 6-8 with dilute hydrochloric acid or sodiumhydroxide. O-(4-dimethylaminoethoxycinnamoyl)fumagillol (1 g) was addedand completely dissolved by stirring at 4° C. If necessary, the pH ofthe final solution was adjusted between 6-8 with dilute hydrochloricacid or sodium hydroxide and filtered through 0.2 μm membrane filter andthe filtrate was lyophilized.

Example 7

Hydroxypropyl-β-cyclodextrin (13 g) was put to mass flask and 60 ml ofdistilled water was added and stirred or subjected to sonication at 4°C. until clear solution was obtained. The pH of the solution wasadjusted in the range of 6-8 with dilute hydrochloric acid or sodiumhydroxide. O-(3,4,5-trimethoxycimamoyl) fumagillol (1 g) was added andcompletely dissolved by stirring at 4° C. If necessary, the pH of thefinal solution was adjusted in a range of 6-8 with dilute hydrochloricacid or sodium hydroxide and filtered through 0.2 m membrane filter andthe filtrate was lyophilized.

Example 8

Potassium phosphate (6.8 g) and hydroxypropyl-β-cyclodextrin (21.67 g)were put to mass flask and 100 ml of distilled water was added andstirred or subjected to sonication at 4° C. until clear solution wasobtained. O-(4-dimethylaminoethoxycinnamoyl)fumagillol (1.67 g) wasadded and completely dissolved by stirring at 4° C. The final solutionwas filtered through 0.2 μm membrane filter and the filtrate waslyophilized.

Example 9

According to the same method as in Example 8 except usingsulfobutylether-7-β-cyclodextrin instead ofhydroxypropyl-β-cyclodextrin, inclusion compound ofsulfobutylether-7-β-cyclodextrin with O-(4-dimethylaminoethoxycinnamoyl)fumagillol was prepared.

Example 10

Potassium phosphate (6.8 g) and hydroxypropyl-β-cyclodextrin (21.67 g)were put to mass flask and 100 ml of distilled water was added andstirred or subjected to sonication at 4° C. until clear solution wasobtained. O-(4-dimethylaminoethoxycinnamoyl)fumagillol⋅oxalate (1.84 g)was added and completely dissolved by string at 4° C. The final solutionwas filtered through 0.2 μm membrane filter and the filtrate waslyophilized.

Example 11

According to the same method as in Example 10 except usingsulfobutylether-7-β-cyclodextrin instead of hydroxypropyl-f-cyclodextrinin Example 10, inclusion compound of O-(4-dimethylaminoethoxycinnamoyl)fumagillol⋅oxalate with sulfobutylether-7-β-cyclodextrinwas prepared.

Example 12

The filtrate obtained in Example 6 was lyophilized. The resultinglyophilized product was dissolved in heavy water (D₂O) and analyzed byusing two-dimensional ¹H-NMR (NOESY). The results are shown in FIG. 1.The cross peaks indicate that there are interactions between fourprotons of O-(4-dimethylaminoethoxycinnamoyl)fumagillol and the protonsof the glucose skeleton of hydroxypropyl-4-cyclodextrin. These crosspeaks were not observed for the spectrum ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol alone. These resultsindicate that O-(4-dimethylaminoethoxycinnamoyl)fumagillol forms aninclusion compound with hydroxypropyl-β-cyclodextrin.

Example 13

The stability 6f the lyophilized powders obtained in Example 6 wascompared with that of O-(4-dimethylaminoethoxycinnamoyl)fumagillol aloneunder storage at 25° C. The residual amount ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol was determined by HPLC. Theresults are shown in Table 6.

TABLE 6 Residual amount of O-(4-dimethylaminoethoxy-cinnamoyl)fumagillol (%) after after after after 1 month 3 month 6 month12 month O-(4-dimethylaminoethoxy- 72.8 54.3 — — cinnamoyl)fumagillolInclusion compound of 99.3 98.7 97.5 93.6 O-(4-dimethylaminoethoxy-cinnamoyl)fumagillol

As in apparent from Table 6, the stability of complex ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin was improved as compared to that ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol alone.

Example 14

The stability of the lyophilized powders obtained in Example 7 wascompared with that of O-(3,4,5-trimethoxycinnamoyl)fumagillol alone at25° C. The residual amount of O-(3,4,5-trimethoxycinnamoyl)fumagillolwas determined by HPLC. The results are shown in Table 7.

TABLE 7 Residual amount of O-(3,4,5-trimethoxy- cinnamoyl)fumagillol (%)after after after after 1 month 3 month 6 month 12 monthO-(3,4,5-trimethoxycinna- 65.3 — — — moyl)fumagillol Inclusion compoundof 99.5 97.7 94.4 93.2 O-(3,4,5-trimethoxycinna- moyl)fumagillol

As in apparent from Table 7, the stability of complex ofO-(3,4,5-trimethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin was improved as compared to that ofO-(3,4,5-trimethoxycinnamoyl)fumagillol alone.

Example 15

The stability of O-(4-dimethylaminoethoxycinnamoyl)fumagillol wasinvestigated in the presence of various concentrations ofhydroxypropyl-β-cyclodextrin in acidic, neutral and basic solutions at50° C. The residual amount ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol in each solution wasdetermined by HPLC. The results are shown in Table 8.

TABLE 8 Concentration of hydroxypropyl-β- Acidic (pH 3.2) Neutral (pH7.2) Basic (pH 11.5) cyclodextrin Inhibition Inhibition Inhibition (w/v%) k_(obs) (h⁻¹)^(a) ratio (%) k_(obs) (h⁻¹) ratio (%) k_(obs) (h⁻¹),ratio (%) 0 0.2042 — 0.0162 — 0.0918 — 2 0.0976 52.20 0.0141 12.960.0816 5.00 5 0.0848 58.47 0.0137 15.43 0.0580 16.55 10 0.0754 63.080.0122 24.96 0.0453 22.77 20 0.0665 67.43 0.0115 29.01 0.0294 30.56^(a)k_(obs): Hydrolysis Rate Constant

As in apparent from Table 8, hydroxypropyl-f-cyclodextrin suppressed thehydrolysis rate of O-(4-dimethylaminoethoxy cinnamoyl)fumagillolsignificantly.

Example 16

Pre-prepared tumor mass (Lewis lung carcinoma) of 8 mm³ wassubcutaneously implanted into the right axillary region of BDF1 mice (4weeks). When the tumor size was 100-200 mm³, mice were divided randomlyinto treatment group and control group. The treatment group wasadministered subcutaneously withO-(4-ethylaminoethoxycinnamoyl)fumagillol or the complex ofO-(4-ethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin at a dose of 30 mg/kg or 120 mg/kg asO-(4-ethylaminoethoxycinnamoyl)fumagillol every other day for 5injections, while the control group was given injections of 0.2 ml ofphosphate buffered saline. The tumors were weighed on the final day, andtumor volume was calculated using the following equation:

Tumor volume (mm³)=a×b ²×0.5

(a: the longest diameter, b: the shortest diameter)Inhibition ratio (IR %) of the treatment group relative to the untreatedcontrol group was calculated using the following equation:

Inhibition Ratio %=(1−Tumor volume of Treatment group/Tumor volume ofControl group)×100 Inhibition Ratio %

(1−Tumor weight of Treatment group/Tumor weight of Control group)×100

The results are shown in Table 9.

TABLE 9 Inhibition Ratio (%), Total Dose Tumor Tissue Tumor Tissue(mg/kg) Volume Weight Control Group 150 0 0 600 0 0 Group administered150 37.7 33.6 with O-(4-dimethyl- 600 63.3 71.4 aminoethoxycinna-moyl)fumagillol Group administered 150 32.2 34.7 with inclusion 600 60.470.8 compound of O-(4- dimethylaminoethoxy- cinnamoyl)fumagillol

As in apparent from Table 9, the inclusion compound ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol exhibits comparableantitumor activity with O-(4-dimethylaminoehoxycinnamoyl)fumagillolalone.

Example 17

O-(4-dimethylaminoethoxycinnamoyl)fumagillol alone and the complex ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin containing the same amount ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol were injected viaintravenous route, and blood level of the drug was determined. As testanimal, 5 male rats were used per 1 group.

Under light ether anesthesia, the femoral arteries and veins of ratswere cannulated with PB-50 polyethylene tubing. After complete recoveryfrom anesthesia, O-(4-dimethylaminoethoxycinnamoyl)fumagillol alone orthe complex of O-(4-dimethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin dissolved in phosphate buffered saline (pH6.2) was administered intravenously to the femoral vein through thecatheter at a dose of 20 mg/kg asO-(4-dimethylaminoethoxycinnamoyl)fumagillol, respectively. Bloodsamples (0.15 ml) were collected via the femoral artery immediatelyafter the dose and at designated time intervals (15, 30, 45, 60, 120,180 and 240 min). The blood samples were centrifuged immediately and theconcentrations of O-(4-dimethylaminoethoxycinnamoyl)fumagillol in theplasma were determined by HPLC.

As apparent in FIG. 2, there were no significant differences between theplasma concentrations of O-(4-dimethylaminoethoxycinnamoyl)fumagillolalone and those of the complex ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin. However, it was advantageous that theadministration of the complex ofO-(4-dimethylaminoethoxycinnamoyl)fumagillol withhydroxypropyl-β-cyclodextrin causes little pain on the injection site incontrast to that of O-(4-dimethylaminoethoxycinnamoyl)fumagillol alone.

INDUSTRIAL APPLICABILITY

The inclusion compound of fumagillol derivative or its salt withhydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrinaccording to the present invention shows improved water-solubility,superior long-term stability at room temperature and reduced irritancyeffect to injection site with unaltered tumor growth inhibitory activitywhen compared to fumagillol derivative alone, and thus may be useful forthe treatment of tumors as an angiogenesis inhibitor.

1. An inclusion compound of a fumagillol derivative or a salt thereofwith hydroxypropyl-β-cyclodextrin, wherein the fumagillol derivative isO-(4-dimethylaminoethoxycinnamoyl)fumagillol. 2.-4. (canceled)
 5. Theinclusion compound of claim 1 characterized in that said fumagillolderivative salt is selected from a group consisting of salts offumagillol derivative with hydrochloric acid, bromic acid, sulfuricacid, phosphoric acid, nitric acid, formic acid, acetic acid,trifluoroacetic acid, oxalic acid, fumaric acid, tartaric acid, maleicacid, methanesulfonic acid, benzenesulfonic acid or para-toluenesulfonicacid.
 6. The inclusion compound in claim 1 characterized in preparing bydissolving hydroxypropyl-β-cyclodextrin in distilled water, and addingfumagillol derivative or its salt under stirring.
 7. The inclusioncompound in claim 1 characterized in that the inclusion compound isprepared by dissolving hydroxypropyl-β-cyclodextrin in distilled water,and adding fumagillol derivative or its salt under stirring afteradjusting the solution pH in a range of 6-8 with dilute hydrochloricacid or sodium hydroxide solution.
 8. The inclusion compound in claim 1characterized in that the inclusion compound is prepared by dissolvinghydroxypropyl-β-cyclodextrin in buffer solution which pH waspre-adjusted in a range of 6-8 with phosphate, and adding fumagillolderivative or its salt under stirring.
 9. The inclusion compound ofclaim 6 characterized in that the inclusion compound is obtained byfurther lyophilization step for the final solution obtained afterstirring.
 10. The inclusion compound of claim 6 characterized in thatmolar ratio of fumagillol derivative or its salt tohydroxypropyl-β-cyclodextrin is 1:1 to 1:10.
 11. A pharmaceuticalcomposition comprising the inclusion compound in claim 1 andpharmaceutically acceptable additives.
 12. The pharmaceuticalcomposition in claim 11 characterized in that the pharmaceuticallyacceptable additive is at least one selected from a group consisting ofpharmaceutically acceptable diluents, buffers, flavors, binders,thickening agent, lubricants and preservatives.
 13. The pharmaceuticalcomposition in claim 12 characterized in that said buffer is phosphatebuffer.
 14. The pharmaceutical composition in claim 11 characterized inthat it is formulated in oral or parenteral preparation.
 15. Thepharmaceutical composition in claim 14 characterized in that saidparenteral preparation is injection.
 16. The pharmaceutical compositionin claim 11 characterized in that it is formulated in sustained-releasedosage form. 17.-18. (canceled)
 19. A lyophilized composition comprisingthe inclusion compound of claim 1.